Briakinumab
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].
Product Specifications
CAS Number
[339308-60-0]
Product Name Alternative
ABT-874
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/briakinumab.html
Purity
99.0
Solubility
H2O
Smiles
[Briakinumab]
Molecular Weight
(143.86 kDa)
References & Citations
[1]Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21 (6) :1329-40. |[2]Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365 (17) :1586-96.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-12; IL-23
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15333392 1 Vial
Lentiviral human COQ2 shRNA (UAS) - Lentiviral human COQ2 shRNA (UAS) (25)
Ask
View Details GTR15119187 1 Vial
Lentiviral human COL4A6 shRNA (UAS) - Lentiviral human COL4A6 shRNA (UAS, iRFP) (100)
Ask
View Details GTR15185648 1 Vial
Lentiviral mouse Rps6ka1 shRNA (UAS) - Lentiviral mouseRps6ka1 shRNA (UAS, GFP) (25)
Ask
View Details 